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Background: Remote follow-up (RFU) after colorectal cancer (CRC) surgery allows delivery of 46 
surveillance tests without the need for regular outpatient clinical appointments. However, little is 47 
known about health related quality of life (HRQoL) in RFU patients. 48 
Methods: EQ-5D, QLQ-C30 and QLQ-C29 questionnaires were distributed to CRC patients enrolled in 49 
a RFU programme. The primary outcome of HRQoL scores was analysed by year of RFU, 50 
demographics, operation-type, stoma and adherence to RFU protocols.  51 
Results:428 respondents (59.3%), mean age of 71years(SD 10.1) and a median RFU time of 2.6years 52 
(IQR: 1.6-4.8 years) were included. 26.6% of patients reported ‘perfect health’. The median EQ-5D 53 
index score was 0.785 (IQR: 0.671-1) and QLQ-C30 Global HRQoL score was 75 (IQR: 58.3-83.3). 54 
Females had significantly lower EQ-5D median score of 0.767 (IQR: 0.666-0.879, p=0.0088). Lower 55 
QLQ-C30 HRQoL scores were seen in stoma patients, median 66.6 (IQR: 58.3-83.3, p=0.0029). 56 
Erectile dysfunction (p=0.0006) and poor body image (p=0.001) were also reported more frequently 57 
in stoma patients. Patients undergoing right-sided resection reported a lower median EQ-5D score of 58 
0.765 (IQR: 0.666-0.879, p=0.028) and higher pain severity (p=0.0367) compared with left-sided 59 
resections. There were 128 (29.4%) patients that breached RFU protocol and were seen in adhoc 60 
colorectal clinics. However, there was no statistical difference in HRQoL between patients who 61 
adhered to or breached RFU protocols. 62 
Conclusions: Overall HRQoL in patients in RFU is good, with no difference in those strictly followed 63 
up remotely. However, females, right-sided resections and patients with stomas may require 64 
additional clinical reviews. 65 
  66 
4 
 
What does this paper add to the existing literature? 67 
Remote follow-up after colorectal cancer surgery allows safe delivery of surveillance tests and 68 
obviates the need for regular clinic appointments. However, there is a paucity of information on 69 
patient reported quality of life within this set-up. This study found that females, right-sided resections 70 
and patients with stomas may require additional clinical reviews.   71 
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 Introduction  72 
Colorectal cancer (CRC) is the 3rd most common malignancy in the UK; in excess of 41,000 new cases 73 
are diagnosed each year(1). With curative surgery as the mainstay of CRC treatment survivorship is 74 
increasing and age standardised five year survival rates are now 60.1%(2). The randomised Follow-75 
up After Colorectal Surgery trial (FACS) found that CEA monitoring (initially 3 monthly for 2 years, 76 
then 6 monthly for 3 years) and CTCAP (6 monthly for 2 years, then annually for 3 years) resulted in 77 
improved detection of potentially curable recurrence(3). NICE thus advocates regular CTCAP,  CEA 78 
level monitoring and colonoscopy to detect recurrence for 5 years after treatment completion(4). 79 
However no consensus exists as to how follow-up should be delivered(5) and significant variation in 80 
clinical practice exists on both a national and international level(6). Clinician led follow-up requires 81 
patients to attend regular clinic appointments over 5 years(7). This method is resource heavy and 82 
increasing survival rates can overwhelm outpatient services(8). Timing of clinic visits may sometimes 83 
adversely affect follow-up schedules and more importantly administrative errors around significant 84 
results or “lost to follow-up “issues present a significant governance risk.  Meta-analysis of 85 
randomised controlled trials has found no evidence that face-to-face follow-up is required for 86 
effective surveillance(9) and attendance at clinical appointment has been recognised to increase 87 
patient anxiety(10).  88 
 ‘Remote’ follow-up (RFU) enables timely delivery of surveillance tests and negates the need for 89 
regular clinic attendance. This form of follow-up, also referred to as ‘personalised stratified follow 90 
up’, forms part of the NHS Long Term Plan for Cancer(11).  Robust protocol driven RFU schemes 91 
have been demonstrated to be safe, acceptable to patients and cost effective(6, 12). Patients 92 
undergo tests at the scheduled interval, results administration can be protocolised and “well 93 
survivors” need only return to clinic if results are abnormal. The potential drawback of RFU is that 94 
problems impacting on quality of life faced by survivors may not be addressed. The National Cancer 95 
Survivorship Initiative emphasises the importance of quality of life assessment in patients living 96 
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beyond a cancer diagnosis(13). Siddika et al (2015) surveyed 100 RFU patients with a non-validated 97 
10 question patient satisfaction questionnaire and found high levels of satisfaction there is a deficit 98 
of research into standardised measures of HRQoL in this patient group patients. The most commonly 99 
used instruments for HRQoL are the EQ-5D developed by the European Quality of Life Research 100 
Foundation (EuroQoL) and the QLQ-C30 created by the European Organisation for Research and 101 
Treatment of Cancer (EORTC). 102 
Aims: Long term HRQoL after CRC surgery in patients under RFU is of interest due to a lack of 103 
literature describing outcomes in this group. The primary aim of this study was to quantify HRQoL in 104 
our RFU population to identify particular patient groups that may benefit from a more personalised 105 




In 2011 Nottingham University Hospitals Trust (NUH) adopted a RFU approach for those who had 108 
undergone surgery for colorectal cancer. Patients are typically reviewed once in a post-operative 109 
clinic to address problems related to surgery and subsequent symptoms. If required at this time 110 
further adjuvant treatment is arranged and delivered by the oncology team. All patients are 111 
simultaneously enrolled into RFU which begins at time of treatment completion. This service is 112 
coordinated and run by a cancer specialist nursing team. Patient demographics and details regarding 113 
their diagnosis and treatment are entered prospectively into a RFU database (Microsoft Access™, 114 
Seattle, USA). A small number of patients at the start of the database were included with 115 
neuroendocrine tumours and polyps but we planned to exclude these from the analysis of CRC. This 116 
database is used to identify when patients require blood tests, CT scans and colonoscopy at 117 
appropriate time intervals (see appendix 1 for full protocol). The team then orders the required 118 
tests, reviews the results, communicates the results to the patient and if abnormal the patient is 119 
referred to the clinician led multi-disciplinary team. Figure 1 illustrates the typical journey of a 120 
patient and entry into the remote follow up programme. It is important to note that during RFU 121 
patients may request to be seen on an ad hoc basis in colorectal clinic if they have any troubling 122 
symptoms requiring further management.  123 
We undertook a cross-sectional study of all patient in RFU using 3 validated questionnaires to ensure 124 
coverage of a wide breadth of HRQoL domains. Prior to distribution permission to use each 125 
questionnaire for the purposes of this study was granted by EuroQol for the EQ-5D-5L(14)and EORTC 126 
for QLQ-C30(15) and QLQ-C29(16). The widely used EQ-5D-5L was selected to provide an insight into 127 
general HRQoL. This uses a 5 point scale (ranging from ‘no problems’ to 'extreme problems’) to 128 
measures everyday function across the 5 domains of mobility, self-care, usual activities, pain and 129 
anxiety. Responses can then be used to generate a single ‘index’ score which is a summary of 130 
respondent’s answers to the 5 domain questions standardised to the general UK population(17). The 131 
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index score can range between -0.594 and 1; 1 corresponds to perfect health and lower than 0 132 
correspond to health states which are ‘worse than dead’(18). 133 
EORTC produces questionnaires to enable HRQoL assessment specifically in cancer patients. We 134 
selected the general oncological QLQ-C30 and the complementary CRC specific QLQ-C29 for use in 135 
this study. The answers to symptom specific questions are recorded on a 4 point scale ranging from 136 
‘not at all’ to ‘very much’. For QLQ-C30 answers to several questions can be combined to provide 137 
overall score for items such as ‘physical function’ and ‘emotional function’. QLQ-C30 also has 2 138 
questions about overall health and quality of life with a 7 point scale ranging from ‘very poor’ to 139 
‘excellent’. For these questions an overall quality of life score can be derived(19). 140 
Data Collection: All patients gave permission to be contacted when they initially consented to RFU 141 
enrolment. Utilising the RFU database 722 living patients were identified as having undergone 142 
surgical intervention for CRC between 1st March 2011 and 31st December 2016. A letter outlining the 143 
project rationale from the colorectal team and the 3 questionnaires were sent to the identified 144 
patients on 21st August 2018. A prepaid envelope was provided to encourage participation and a 145 
window of 4 months was allocated for patients to return the questionnaires to maximize response 146 
rate. On 21st December 2018 returned questionnaires were collated.  147 
Questionnaires were produced in a computer readable format. Returned questionnaires were 148 
scanned and transformed into an electronic database using Teleform Scan Station, Teleform Reader 149 
and Teleform Verifier software produced by OpenText™(20). At the time of scanning all software 150 
output was manually checked against the physical questionnaires to ensure accurate transfer of 151 
information and corrected accordingly. Ambiguous responses and questions left blank were treated 152 
as missing data. The electronic output was second checked by an external validator (A Gupta) 153 
against the physical forms and any discrepancies were amended.  154 
For patients on the database demographics, year of RFU, site of cancer, operation type and 155 
recurrence details are collected prospectively. We undertook retrospective review of this 156 
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information for all questionnaire returners to ensure accuracy. Further data was collected including 157 
Duke’s stage at operation, operative details, presence of stoma, whether neo-adjuvant and/or 158 
adjuvant treatment was received, site of cancer recurrence. Retrospective database review and 159 
additional data was obtained from electronic hospital records. Patients who were seen by a 160 
colorectal surgeon after entry into RFU were identified as having ‘breached protocol’ and these 161 
patients provided a comparative group to those who were purely followed up remotely. Details of 162 
any clinic attendance within the year prior to questionnaire completion were also recorded. 163 
Operation was categorised into ‘right-sided resection’, ‘left-sided resection’ or ‘other colorectal 164 
resection’ (Appendix 2). This involved review of clinic letters, multi-disciplinary team outcome 165 
letters, discharge summaries, pathology results and follow-up imaging reports. Demographic data 166 
for non-responders was also collected for comparison. Questionnaire responses and clinical data 167 
were combined for subsequent analysis. 168 
We categorised age into 3 groups based on their age at time of questionnaire completion (<65, 65-169 
74, 75+). We also grouped patients by resection side to compare overall HRQoL and symptom 170 
experience in patients who underwent either right or left-sided resections. For the purposes of this 171 
analysis results from patient who underwent ‘other colorectal resections’ were excluded (appendix 172 
2) 173 
Patients with a stoma at time of questionnaire completion were identified from the answer to 174 
Question 48 “Do you have a stoma bag (colostomy/ileostomy)?” on the QLQ-C30. Time elapsed since 175 
each patient’s operation was used to stratify year of remote follow-up into Year 1, Year 2, Year 3 and 176 
Year 4+.  177 
Comparative groups 178 
Results for EQ-5D domains were compared to published norms for the general UK population(21). 179 
Overall HRQoL scores and EQ-5D domains were also analysed between patients who breached 180 
protocol and those did not. Further comparisons were made for patients who were seen in the year 181 
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prior to questionnaire completion to determine whether recent breaches of protocol had any 182 
influence on HRQoL.  183 
Data analysis: All statistical analysis was performed using Stata 12.0(22). EQ-5D index scores were 184 
calculated using the Crosswalk Index Value Calculator(17) which is the method advocated by 185 
NICE(23). For the QLQ-C30 symptom, function and overall global quality of life scores were 186 
calculated using the linear transformation method described in the EORTC manual(19).  187 
Descriptive statistics were used to report demographics, operation specific factors and cancer 188 
specific features. Parametric variables were reported by mean and standard deviation, non-189 
parametric variables were reported using the median and interquartile range. Key areas of interest 190 
were overall HRQoL scores, HRQoL at different stages of RFU, HRQoL in patients who breached 191 
protocol, symptomatology and if reported experience differed in patient who had right or left- sided 192 
resections. Tests of hypothesis included chi square testing for categorical variables, t-test for 193 
parametric variables Kruskal Wallis test for non-parametric variables. A p-value of less than 0.05 was 194 
used to determine statistical significance.  195 
Outcomes in this study were presented in terms of EQ-5D index and QLQ-C30 global quality of life 196 
scores, percentage reporting problems for each functional domain on EQ-5D, results of symptom 197 
scales for QLQ-C30 and individual symptom questions on QLQ-C29. This service evaluation was 198 
conducted in association with the MacMillian Cancer Centre as part of our continual assessment of 199 
our cancer pathway. 200 




In total 722 patients were contacted and 463 (64.1%) responses were received (Figure 2. 203 
Questionnaires were not completed in 259 (35.9%). 3 patients died during the data collection period 204 
and 3 declined to participate. The remaining 253 patients had not returned the form at 4 months 205 
and were hence assumed to have declined to participate.  206 
Demographics of responders and non-responders were compared to identify any heterogeneity 207 
between these groups (Table 1). 42.5% of responders were female compared with 44.8% of non-208 
responders; chi square demonstrated no significant difference (chi2= 0.34, p=0.56). There was 209 
however a significant difference in mean age between the groups; mean age of non-responders was 210 
67.5 years (S.D. 10.2) versus 71.1 years (S.D 12.5) in responders (t(720)=4.1 p<0.0001). 211 
Missing questionnaire data: Of the 428 patients included in the data analysis; 35 responders were 212 
excluded as they had undergone polypectomy alone .427 returned all 3 questionnaires. One patient 213 
returned the completed EQ-5D and QLQ-C30 but did not return the QLQ-C29. The majority of 214 
questionnaires were filled out completely; for EQ-5D answers were complete in 98.4%, for QLQ-C30 215 
98.6% and for QLQ-C29 91.6%.  216 
Demographics and cancer specific features: 57.8% of included patients were male, mean age was 217 
71.3 years (S.D. 10.1) and median time in remote follow up was 2.6 years (IQR: 1.6-4.8 years). Details 218 
of cancer specific features are summarised in Table 2; in those with cancer recurrence median time 219 
from operation to recurrence was 1.4 years (IQR 0.9-2.7 years). 220 
Details of surgical treatment and stoma: Specific operation types included in each category are 221 
detailed in appendix 2. 27.1% of patients had a stoma at time of questionnaire completion.  222 
Demographics of patients who breached protocol: The number of responders who breached 223 
protocol by being seen in clinic after entry in to RFU was 126 (29.4%); 52 (12.2%) of which were seen 224 
within the year prior to questionnaire completion.  For gender there was no significant difference 225 
12 
 
between those who were seen in clinic and those who were not (chi2 =1.51, p=0.22). However 226 
patient breaching protocol were significantly younger (chi2 =7.79, p=0.05) and were significantly 227 
more likely to have undergone a left sided resection or APER (chi2 =7.93, p=0.005).  Further 228 
demographic details are outlined in table 3.  229 
HRQoL overall: 2 overall measures of quality of life were utilised; the index score from EQ-5D and 230 
the global quality of life score from QLQ-C30. The distribution of results for each score was 231 
negatively skewed; hence we used non-parametric methods to test statistical significance. For QLQ-232 
C30 global HRQoL the median score was 75.0 (IQR: 58.3 – 83.3). For EQ-5D index score the median 233 
was 0.785 (IQR 0.671-1) which corresponds to a health state with no problems with mobility, self-234 
care or depression, moderate problems in usual activities and slight problems with pain. Figure 3 235 
summarises percentage of patients reporting ‘no problems’ versus ‘problems’ across EQ-5D 236 
functional domains. 26.6% reported no problems in any domain and 10.7% reported problems in 237 
every domain.  238 
HRQoL scores by demographics, cancer specific features, stoma and adherence to protocol: Table 239 
4  presents median quality of life scores across the proposed subgroups. No statistically significant 240 
differences were found for each HRQoL measure for site of tumour or those who had neoadjuvant 241 
and/or adjuvant treatment versus surgery alone. No significant differences between patient who 242 
adhered strictly to RFU protocol and those who breached protocol were identified on overall HRQOL 243 
scores. Furthermore, there was no significant difference in patients who breached protocol in the 244 
year prior to questionnaire completion. EQ-5D index scores were found to be significantly lower in 245 
females (p=0.009) and in patients with cancer recurrence (p=0.0092). QLQ-C30 scores and EQ-5D 246 
index values demonstrated a significant variation across age groups on analysis. 5D-5L index values 247 
by age group peaked at 65-74 years (median 0.837, IQR: 0.698-1). Lower median scores of 0.768 for 248 
those <65 years (IQR: 0.623-1) and the 75+ group (IQR: 0.671-0.879). Similarly for QLQ-C30 median 249 
scores this pattern was seen. QLQ-C30 scores proved significantly lower in patient with a stoma 250 
(p=0.003). Gender across the age groups was homogenous (chi2 = 0.59, p= 0.74) and there was no 251 
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statistically significant difference in stoma presence (chi2=5.68, p=0.058). Recurrence of cancer 252 
impacted EQ-5D scores negatively (p=0.009) and higher rates of recurrence were seen in patients 253 
<65 years and over 75 (chi2= 10.75, p=0.005). There were however no differences between age 254 
groups and stage at time of operation (chi2 = 4.36, p = 0.59).   255 
Right and left-sided resection: No significant difference was demonstrated between right or left 256 
resection groups in terms of QLQ-C30 score. However, a statistically significant difference between 257 
EQ-5D index scores was noted; lower scores were reported by patients who underwent right colonic 258 
operations (p=0.028). A perfect health score of 1 was reported by at least 25% of patients in the left 259 
group; this ceiling effect was only seen in 10% of the patients who underwent right-sided resections. 260 
There was no difference between the gender distribution of these groups (chi2=1.68, p=0.20); age 261 
was significantly lower in patients undergoing left-sided resections (Mean = 70.5 years, S.D= 9.5 262 
years) compared to right-sided (Mean=73.9 years, S.D=9.8 years) (p=0.005). A significantly higher 263 
number of patients in the left group had stomas (chi2= 57.9, p<0.001). 264 
HRQoL score by year of RFU: Overall the trend of QLQ-C30 score by year of follow-up was stable. 265 
Index scores by year were highest at Year 1 (median 0.837, IQR: 0.723-1) and lowest in the 3rd year 266 
(median 0.750, IQR: 0.592-1); Figure 4 illustrates the overall trend of index score by year. No 267 
significant difference was found when EQ-5D index (p=0.265) and QLQ-C30 scores (p=0. 8084) were 268 
stratified by year of RFU. 269 
EQ-5D domain comparison (table 5): EQ-5D domain scores for pain, activity, mobility, self-care and 270 
anxiety were compared to published norms from a cohort of unselected members of the general UK 271 
population(21). Across all domain’s patients within RFU reported significantly more pain (p<0.001) 272 
and anxiety (p<0.001) and higher levels of anxiety (p<0.001), mobility problems (p<0.001) and 273 
difficulty with self-care (p=0.001). Domains were compared between patients adhering to RFU 274 
protocol and those who breached protocol. Statistically significant differences noted were higher 275 
rates of pain (p=0.05) and more limitation to activity (p=0.043) in the group that breached protocol.  276 
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Symptom reporting: Abdominal symptoms such as pain were reported in 28.5% and bloating in 277 
41.0%. Constipation affected 34.7% of responders and 33.9% reported diarrhoea. Blood in the stool 278 
was noted by 4.8% and stool containing mucus was experienced by 12.7%.  279 
Sexual function overall: In total 41.9% reported feeling less attractive as a result of their disease or 280 
treatment. No sexual interest was reported in 29.5% of males and 65.1% of females. In males, age 281 
had a significant influence over sexual interest (chi2=20.8, p<0.001) but for females this was not 282 
observed (chi2 6.68, p=0.083). Erectile dysfunction was experienced by 74.6% of male responders 283 
and this was more prevalent as age group increased (chi2=7.78, p=0.020). 106 female responders 284 
(80.3%) provided an answer to “Did you have pain or discomfort during intercourse?” 21.7% 285 
reported dyspareunia and this was significantly higher in the youngest age group (chi2= 20.01, 286 
p<0.001).  287 
Symptoms in stoma patients: Rates of abdominal pain and bloating were not significantly different 288 
between those with a stoma and without (p=0.72, p=0.23). Trouble with stoma care was reported in 289 
25%. Stoma presence was contributed negatively to body image with problems reported in 66.7% 290 
compared to 43.0% of patients without a stoma (chi2=18.5940, p<0.001). No difference in sexual 291 
interest was noted between patient with and without a stoma. Erectile difficult was significantly 292 
higher in stoma patients (chi2=7.5689, p=0.006). 293 
Symptoms by right and left resection: Comparisons were made between patients who had right or 294 
left-sided resections. Reported experience of abdominal pain (32.8% right, 25.8% left) and bloating 295 
(46.7% right, 38.5% left) was similar in these groups (p=0.131 for pain and p=0.106 for bloating). Pain 296 
severity was however higher in the group who had right colonic surgery (p=0.0335).  For 297 
constipation and diarrhoea no significant difference was observed in symptom reporting or severity. 298 
No differences were observed for sexual interest or function. Left-sided resection patients reported 299 
feeling less masculine/feminine as a result of treatment (chi2= 6.2267, p=0.012) and less attractive 300 
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(chi2 =3.9232, p=0.048). No differences were observed across functional scales or symptoms scales 301 




Discussion  304 
This study is the first to examine HRQoL in operatively managed CRC patients enrolled in a RFU 305 
programme. We have used validated questionnaires to quantify HRQoL and to understand the 306 
symptoms experienced by patients in RFU. Reassuringly HRQoL scores were demonstrated to be 307 
consistently high and similar regardless of time since operation, treatment and cancer site. Lower 308 
scores were associated with being female, cancer recurrence, stoma presence and right-sided 309 
resections. Frequently reported symptoms included abdominal pain (28.5%), bloating (41.0%), 310 
constipation (34.7%) and diarrhoea (33.9%). No difference in these symptoms was observed relating 311 
to stoma presence or side of operation; however right-sided resection patients reported higher pain 312 
severity (p=0.0335). Body dissatisfaction and erectile dysfunction rates were high. Our results 313 
suggest that female patients, who are older with right sided resections may require additional 314 
clinical reviews rather than just remote follow up. Additionally support should be offered regarding 315 
sexual dysfunction to those patients in RFU programmes. 316 
Strengths of this study include the response rate of 64.1% which is higher than that of similar studies 317 
in long term CRC survivors(24-26) and the low number of missed answers. Possible limitations are 318 
that questionnaire responders were significantly older than non-responders and hence the results 319 
may not be reflective of the experience of younger patients. No baseline data was collected; we 320 
therefore only present a snapshot of HRQoL within a RFU population and in comparison to the 321 
subgroup of patients who breached protocol, other studies and population norms. Co-morbidity has 322 
been shown to negatively impact HRQoL in CRC patients(27); our study did not examine co-323 
morbidity as it was felt that retrospective collection of this data would be unreliable due to 324 
inconsistency in local reporting. Similarly lower socio-economic status negatively influences 325 





Comparative groups: 329 
Younger patients, those with who underwent left sided resections and those with recurrent cancer 330 
were more likely to breach protocol and be seen in clinic. No overall differences were found in the 331 
subgroup of patients who breached protocol by being seen in clinic following entry into RFU. This 332 
suggests that the extra support required by these patients was provided appropriately through an ad 333 
hoc clinic visit. 334 
EQ-5D results in a sample reflective of the English population also provides a useful comparison(21). 335 
As expected our population had a statistically significantly higher rate of problems across all domains 336 
compared to the general population. Pain was the most frequently reported problem; 56.0% 337 
reporting at least ‘slight problems’ with pain. Domain differences were compared based on protocol 338 
adherence. Across all domains problem reporting was higher in patients who breached protocol; yet 339 
pain and activity limitation were the only domains to reach statistical significance. A significant 340 
difference may be seen for every domain if a larger sample size were surveyed. This data may partly 341 
explain why these patients breached protocol; clinician review being sought by those patients with 342 
ongoing problems.  343 
Our findings reiterate previous UK based studies which have found stoma presence(25, 29) and 344 
cancer recurrence(25) negatively impact HRQoL in CRC patients. There is variation in the reported 345 
influence of gender on HRQoL depending on the population studied. In general population terms it is 346 
well recognised that females report lower HRQoL scores than their male counterparts(30). Finnish 347 
and Iranian studies focusing on CRC patients found no difference between male and female 348 
responses to EQ-5D and QLQ-C30 data(31, 32). We found significantly lower score in females which 349 
has been previously observed in UK and Japanese cohorts(25, 33). Within our RFU patients high 350 
rates of abdominal symptoms and sexual dysfunction were found and both of these sequelae have 351 
been widely reported in CRC survivors(26, 34-37). Persistence of abdominal symptoms over time was 352 
reported in CRC patients at 1 and 3 years post diagnosis and our findings reflect this(29).   353 
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Downing et al (2015) reported 34.5% of CRC patients between 12-36 months post diagnosis stated 354 
that they had ‘no problems’ in any EQ-5D functional domain. Comparatively in our cohort ‘no 355 
problems’ were reported in 26.6% and higher rates of problem reporting across each domain apart 356 
from self-care. These results can perhaps be attributed to demographic differences between study 357 
populations in particular, within our cohort 42.2% were female versus the 37.2% in Downing et al 358 
(2015). The percentage of patients <65 years was less in our study (27.3% vs 33.0%) and >75  years 359 
was greater (39.9% vs 31.1%).  360 
Another UK study utilising QLQ-C30 scores in CRC patients >2 years post diagnosis reported no 361 
significant difference between median scores of colonic and rectal cancer patients(24). Similarly we 362 
found no significant difference between rectal and colonic cancer patients. Recent publications have 363 
primarily focused on HRQoL in anterior resection patients. An international study demonstrated that 364 
low HRQoL correlates with severity of LARS(34) and this impact has also been shown to persist over 365 
time(35).There is however a deficit of literature comparing outcomes between right and left-sided 366 
resection patients. One small case control study which reported no difference in EQ-5D scores 367 
stratified by resection side(38). Recently Buchli et al (2018) reported on HRQoL and LARS stratified 368 
by resection side(39). This study found that major LARS symptoms were more frequently 369 
experienced by right-sided resection patients and that major symptoms were an independent 370 
predictor of lower HRQoL scores.  Our data corroborates this within our study population lower 371 
HRQoL scores were associated with right-sided resection. Our findings highlight that the long term 372 
HRQoL outcomes of right-sided resection patients should be of clinical concern. The outcomes in this 373 







CONCLUSION:  379 
Our findings provide us with confidence that patients enrolled in our RFU programme experience 380 
high HRQoL which remains stable. We have identified factors which contribute negatively to HRQoL; 381 
this information will be a useful tool in future service planning and patient counselling. Patients who 382 
breached protocol did not differ on overall HRQoL score but were more likely to experience pain and 383 
activity limitation. Right-sided resection patients reported significantly worse HRQoL and we 384 
therefore highlight this patient group as a focus for further investigation.  Overall these findings 385 
suggest that even within a RFU setting, targeted clinics dedicated to addressing these specific 386 
problems and patient groups could mitigate deterioration in HRQoL after CRC surgery. A targeted 387 
clinic for these patients is being planned for those in the 3rd year of follow-up as this was the post-388 
operatively time point with the lowest overall HRQoL scores. Given the ongoing global challenges 389 
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Table 1: Demographics of responders vs non-responders 542 
 543 
 544 






Overall 463 64.1 259 35.9 - 
Male 266 57.5 143 55.2 - 
Female 197 42.5 116 44.8 0.56 
Mean age 71.7 - 67.5 - <0.01* 
26 
 
Table 2: Demographic and cancer specific details by site of tumour 546 
 547 
*Dukes stage not recorded or not applicable due to complete response to neoadjuvant treatment 548 





Site of cancer Colonic % Rectal % Overall % P 
values  
288 67.3 140 32.7 428 100.0  
Gender   
Male 156 54.2 91 65.0 247 57.8  




<65 71 24.7 47 33.6 118 27.6  
65-74 89 30.9 50 35.7 139 32.5  
75+ 128 44.4 43 30.7 171 39.9 0.02* 
Mean age 72.4 - 69.1 - 71.3 -  
Year of remote follow-
up 
  
Year 1 30 10.4 13 9.3 43 10.1  
Year 2 73 25.3 38 27.1 111 25.9  
Year 3 61 21.1 39 27.9 100 23.4  
Year 4+ 124 43.1 50 35.7 174 40.6 0.35 
Dukes stage at 
operation 
  
A 63 21.9 49 35.0 112 26.1  
B 120 41.7 39 27.9 159 37.2  
C 102 35.4 35 25.0 137 32.0 <0.01* 
D 1 0.3 1 0.7 2 0.5  
Unknown/Not applicable* 2 0.7 16 11.4 18 4.2  
Treatment   
Neoadjuvant** 5 1.7 29 20.7 34 7.9  
Adjuvant 108 37.6 25 17.9 133 31.1  
Neoadjuvant + adjuvant 5 1.7 15 10.7 20 4.7  
Only surgical 170 59.0 71 50.7 241 56.3 <0.01* 
Recurrence   
Local 7 1.6 3 2.1 10 2.3  
Distal 33 11.5 14 10.0 47 11.0  
Overall 40 13.1 17 12.1 57 13.3  
No recurrence  248 86.9 123 87.9 371 86.7 0.93 
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Table 3: Demographic and cancer specific details by adherence to RFU protocol.  554 
 555 











% No* % Overall % P 
values  
302 70.6 126 29.4 428 100.0  
Gender   
Male (n=247) 180 59.6 67 53.2 247 57.7  




<65 years (n=118) 72 23.8 46 36.5 118 27.5  
65-74 years (n=139) 101 33.5 38 30.2 139 32.5  
75+ years (n=171) 129 42.7 42 33.3 171 40.0 0.02* 
Mean age 68.6 - 65.0 - 71.3 -  
Year of remote follow-up   
Year 1 (n=43) 37 12.3 6 4.8 43 10.1  
Year 2 (n=111) 72 23.8 39 31.0 111 25.9  
Year 3 (n=100) 72 23.8 28 22.2 100 23.4  
Year 4+ (n=174) 121 40.1 53 42.0 174 40.6 0.076 
Tumour site   
Colonic (n=288) 216 71.5 72 57.1 288 67.3  
Rectal (n=140) 86 28.5 54 42.9 140 32.7 0.004 
Resection site   
Right (n=143) 113 37.4 27 23.7 140 34.3  
Left (n=268) 181 59.9 87 76.3 268 65.7 0.005 
Oncological treatment   
Surgery alone (n=241) 178 58.9 63 50.0 241 56.3  
Neoadjuvant +/- Adjuvant 
(n=187) 
124 41.1 63 50.0 187 43.7 0.078 
Recurrence    
No recurrence (n=371) 271 89.7 100 79.4 371 86.7  
Recurrence (n=57) 31 10.3 26 20.6 57 13.3 0.004 
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Table 4: Quality of life measure results summarised by demographic, cancer related and operation 563 
specific details  564 
 
Health related quality of life measure 
 
EQ-5D index score 
 
QLQ-C30 quality of life score 
 
Overall for study population (n=428) 0.785 (IQR: 0.671-1) 75 (IQR: 58.3-83.3) 
Gender 
Male (n=247) 0.836 (IQR: 0.679-1) 83.3 (IQR: 66.7-91.7) 
Female (n=181) 0.767 (IQR: 0.666-0.879) 75 (IQR: 54.1-83.3) 
p-value 0.009* 0.090 
Age Group 
<65 years (n=118) 0.768 (IQR: 0.654-1) 75 (IQR: 50-91.6) 
65-74 years (n=139) 0.837 (IQR: 0.698-1) 83.3 (IQR: 66.7-91.6) 
75+ years (n=171) 0.767 (IQR: 0.671-0.879)  75 (IQR: 58.3-83.3)  
p-value 0.05* 0.01* 
Year of remote follow-up 
Year 1 (n=43) 0.837 (IQR: 0.723-1) 83.3 (IQR: 58.3-83.3) 
Year 2 (n=111) 0.7955 (IQR: 0.683-1) 83.3 (IQR: 66.7-83.3) 
Year 3 (n=100) 0.750 (IQR: 0.592-1) 75 (IQR: 58.3-83.3) 
Year 4+ (n=174) 0.790 (IQR: 0.671-0.879) 75 (IQR: 58.3-91.7) 
p-value 0.26 0.80 
Tumour site 
Colonic (n=288) 0.768 (IQR: 0.671-0.906) 75 (IQR: 58.3-83.3) 
Rectal (n=140) 0.795 (IQR: 0.671-1) 79.1 (IQR: 58.3-83.3) 
p-value 0.22 0.78 
Oncological treatment 
Surgery alone (n=241) 0.795 (IQR: 0.679-1) 75 (IQR: 66.7-83.3) 
Neoadjuvant +/- Adjuvant (n=187) 0.778 (IQR: 0.647-1) 83.3 (IQR: 58.3-83.3) 
p-value 0.52 0.98 
Recurrence 
No recurrence (n=371) 0.795 (IQR: 0.683- 1) 83.3 (IQR: 66.7-83.3) 
Recurrence (n=57) 0.762 (IQR: 0.498-0.848) 75 (IQR: 50-87.5) 
p-value 0.009* 0.41 
Resection side  
Right-sided resection (n=140) 0.765 (IQR: 0.666-0.879) 75 (IQR: 58.3-83.3) 
Left-sided resection (n=268) 0.813 (IQR: 0.679-1) 83.3 (IQR: 66.7-91.7) 
p-value 0.028* 0.19 
Stoma at time of questionnaire completion  
No stoma (n=312) 0.795 (IQR:0.681-1) 83.3 (IQR:62.5-91.7) 
Stoma(n=116) 0.778 (IQR: 0.629-0.906) 66.6 (IQR: 58.3-83.3) 
p-value 0.19 0.003* 
Protocol adherence  
Yes, no clinic appointments within the 
RFU (n=296) 
0.8025 (IQR: 0.6865-1) 83.3 (IQR: 58.3-83.3) 
No, ad hoc clinic appointment within 
RFU (n=124) 
0.74 (IQR: 0.642-0.879) 75 (IQR:58.3-83.3) 
p-value 0.0649 0.1105 





Table 5: Our results for EQ-5D problem reporting overall, in comparison to the general population. 568 





Self-care % Activity 
% 
Pain % Anxiety % 
Our study; English CRC patients under remote 













English population reporting problems using 












P-value p<0.001* p<0.001* p<0.001* p<0.001* p<0.001* 
Protocol Adherence  





No, protocol breached and seen in clinic after 












Chi2, p value  0.520 0.176 0.043* 0.05* 0.804 
*statistically significant results  569 
 570 




Figure 1: timeline illustrating typical journey of patients through diagnosis, treatment and RFU. 573 
 Figure 2: Flowchart to illustrate questionnaire response and subsequent details of included and 574 
excluded responders. 575 
Figure 3: Bar Chat showing percentage of patients reporting problems vs no problems across EQ-576 
5D functional scales 577 
Figure 4: Box Plot summarising EQ-5D index scores by year of remote follow up 578 
 579 
